Beckman Laser Institute
  • About Us
      • About Us
      • Mission & Vision
      • Message From the Founding Director
      • History
      • By the Numbers
      • Employment
      • News
  • Medical Clinic
      • Medical Clinic
      • Conditions & Treatments
      • Why Choose Us
      • Clinical Research Protocols
      • Our Physicians
      • Our Clinic Team
  • Research
      • Research
    • Core Research
      • Modeling & Computation
      • Multimodal Endoscopy
      • Microscopy & Microbeams
      • Diffuse Optical Imaging
      • Laser Therapy
    • Research Programs
      • COVID-19 RESEARCH
      • Medical Applications
      • Laser Microbeam Program (LAMP)
      • Wearable Sensors
    • Shared Resources
      • Shared UCI Access Resources
  • Education & Outreach
      • Education & Outreach
      • Prospective Students
      • Access to Careers in Engineering and Sciences (ACES)
      • Publications
      • Mechanical Ventilation Amid COVID
      • Leaders in Light
      • Multiscale Biophotonics Training Program
      • Events
      • LASER Magazine
      • Course Catalog
  • Industry
      • Industry
      • Photonic Incubator
      • Technology Transfer
      • Patents
      • Convergence Optical Sciences Initiative (COSI)
      • Corporate Partners
      • Advisory Board
  • People
      • People
      • Our Faculty
      • Our Founders
      • Directory
      • Our Research Team
      • Our Research Management Team
      • Our Administrative Team
  • Giving
      • Giving
      • Donate Online
  • How to Give
  • Ways to Give
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Blog - Latest News

Botvinick to Develop First-of-its-Kind Diabetes Monitor

October 4, 2021/ News /by Gabrielle Comfort

Elliot Botvinick, professor of biomedical engineering, has been awarded a three-year, $3.5 million grant from The Leona M. and Harry B. Helmsley Charitable Trust to further the development of an innovative continuous-use monitor for those with Type 1 diabetes. The first-of-its kind device will simultaneously measure insulin, glucose, lactate, oxygen and the ketone body beta-hydroxybutyrate with a single probe inserted just beneath the skin.

Called iGLOBE (Insulin + Glucose + Lactate + Oxygen + Beta-HydroxybutyratE) LifeStrip, the monitor utilizes light and chemistry to provide sensing capabilities for multiple analytes, which can be critical for controlling blood glucose and detecting possible dangerous events. The device will include continuous insulin monitoring and improve dosing efficacy by providing real-time feedback on the dynamics of insulin-pump therapy as well as real-time estimates of a patient’s sensitivity to the insulin.

It is also important to monitor blood glucose in those with Type 1 diabetes, known as insulin dependent diabetes. When blood glucose is elevated above normal values, called hyperglycemia, the body produces a chemical called beta-hydroxybutyrate. Elevated beta-hydroxybutyrate is associated with diabetic ketoacidosis, a dangerous condition, which can result in hospitalization or death. iGLOBE monitors this chemical to indicate dangerous levels and ensure automated insulin delivery functions properly.

Monitoring lactate, produced during exercise, is also important, as it can indicate changing metabolic states, which can lead to changes in blood glucose hours after exercise. This will improve glucose prediction and improve insulin dosing. “Clinical evidence suggests that both beta-hydroxybutyrate and insulin sensing would improve outcomes and decrease the rates of hospitalization, severe morbidity and death associated with hypo- and hyperglycemia,” said Botvinick, who is also associate director of UCI’s Edwards Lifesciences Center for Advanced Cardiovascular Technology and professor of surgery at UCI Beckman Laser Institute (BLI).

The addition of beta-hydroxybutyrate and insulin monitoring capabilities has the potential to be life-altering. “When taken together, glucose, lactate, beta-hydroxybutyrate and insulin monitoring can transform the care of people with Type 1 diabetes,” Botvinick said. “iGLOBE can improve glucose control, compensate for glucose variations associated with exercise, inform of possible or current diabetic ketoacidosis and inform of failing or failed insulin delivery.”

Botvinick is collaborating with Gregory Weiss, UCI professor of chemistry, molecular biology and biochemistry; and David O’Neal, M.D., professor of endocrinology at Australia’s University of Melbourne. The team includes John Weidling, BLI associate project scientist, and biomedical engineering graduate students Toni Wilkinson and Dat Nguyen.

Click here to read UCI Department of Biomedical Engineering Discovery magazine.

Gabrielle Comfort

Author: Gabrielle Comfort

Share this entry
  • Share on Facebook
  • Share on X
  • Share on LinkedIn
  • Share on Reddit
  • Share by Mail
https://bli.uci.edu/wp-content/uploads/2022/08/Elliot-Botvinick.jpg 1053 1600 Gabrielle Comfort https://www.bli.uci.edu/wp-content/uploads/2017/09/white_transparent-1.png Gabrielle Comfort2021-10-04 10:55:002022-08-19 11:07:59Botvinick to Develop First-of-its-Kind Diabetes Monitor
Search Search

Categories

  • News
FOLLOW US ON SOCIAL MEDIA
  • Link to X_icon
  • Link to Facebook
  • Link to LinkedIn
  • Link to Youtube
  • Link to Instagram
  • Support BLIMC❤️
  • Contact US
  • For Staff
Link to: Nature Methods Profiles Michelle Digman Link to: Nature Methods Profiles Michelle Digman Nature Methods Profiles Michelle Digman Link to: Berns Recognized for Biomedical Optics Contributions Link to: Berns Recognized for Biomedical Optics Contributions Berns Recognized for Biomedical Optics Contributions
Scroll to top Scroll to top Scroll to top
Loading...

Insert/edit link

Enter the destination URL

Or link to existing content

    No search term specified. Showing recent items. Search or use up and down arrow keys to select an item.